RecruitingPhase 3NCT07003984
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Studying Chikungunya
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bavarian Nordic
- Principal Investigator
- Patrick Ajiboye, MDBavarian Nordic A/S
- Intervention
- CHIKV VLP vaccine(biological)
- Enrollment
- 720 enrolled
- Eligibility
- 1-11 years · All sexes
- Timeline
- 2025 – 2028
Study locations (15)
- ARK Clinical Research, LLC, Fountain Valley, California, United States
- Emerson Clinical Research Institute- DC, Washington D.C., District of Columbia, United States
- Acevedo Clinical Research, Miami, Florida, United States
- Hope Research Network, Miami, Florida, United States
- Velocity Clinical Research-Omaha, Omaha, Nebraska, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- KidCare Pediatrics, Beaumont, Texas, United States
- Velocity Clinical Research - Salt Lake City, West Jordan, Utah, United States
- CARE CT Group Inc., Dasmariñas, Cavite, Philippines
- HIMC Research and Development on Medical Sciences, Imus, Cavite, Philippines
- Silang Specialist Medical Center, Silang, Cavite, Philippines
- University of Perpetual Help DALTA Medical Center, Biomedical Research Institute, Las Piñas, National Capital Region, Philippines
- Institute of Child Health and Human Development, University of the Philippines, Manila, National Capital Region, Philippines
- University of the Philippines-Philippine General Hospital, Manila, Philippines
- CMRC Headlands LLC, San Juan, Puerto Rico, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07003984 on ClinicalTrials.govOther trials for Chikungunya
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07555392A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Bharat Biotech International Limited
- ENROLLING BY INVITATIONNCT07347002Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07254702Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ACTIVE NOT RECRUITINGNCT07163845Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07520279Xpert® Tropical Fever Test on GeneXpert® Edge X SystemCepheid
- ACTIVE NOT RECRUITINGNCT06651372The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return TravelersUniversity Hospital, Strasbourg, France
- RECRUITINGNCT07120724Real-World Study on Chinese Medicine for Treating Chikungunya FeverGuangzhou University of Traditional Chinese Medicine
- RECRUITINGPHASE4NCT06928753Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La RéunionCentre Hospitalier Universitaire de la Réunion